Thermo Fisher Bioproduction Insights

  1. Effect Of AOF Peptone Supplementation In Batch And Fed Batch Modes 5/10/2024

    This study focuses on AOF peptones and their impact on cell density, viability, and mAb titers, with results suggesting that peptones can enhance mAb titers.

  2. Animal-Origin Free Peptones Enhance Adenovirus Production 5/10/2024

    This study evaluates the use of AOF peptones in the production of the adenoviral vector used in vaccine delivery and gene therapy.

  3. The Value Of Premium Gibco Peptones 5/10/2024

    Achieve the optimal nutritional balance with diverse supplements tailored for your specific bioprocess that can be added to maintain a nutritionally balanced medium.

  4. Explore A High-Performing Basal Medium And Feed Pairing 5/8/2024

    A customer sought to replace a chemically defined CHO medium with a more efficient medium and feed pairing strategy in bioreactors.

  5. Advancing Cell Therapy Manufacturing: Rapid Sterility Testing 5/7/2024

    The rapid sterility test kit used in the study was able to quickly detect bacteria and fungi in complex cell therapy product matrices, detecting six species listed in USP chapter <71>.

  6. Enabling CDMOs To Focus On Core Priorities 4/26/2024

    Explore innovative solutions for CDMO's striving to remain competitive as the biopharmaceutical market grows and evolves.

  7. Accelerating SARS-CoV-2 Immunotherapy Speed To Clinic 4/26/2024

    A clinical-stage biotherapeutics company developing a COVID-19 immunotherapy searched for a solution to the difficulties it faced in scaling up its manufacturing operations due to limited resources.

  8. Understanding Viral Clearance During Anion-Exchange Chromatography 3/26/2024

    A design of experiments (DoE) study examined the anion-exchange process in general and to draw possible correlations between such properties and overall viral clearance capability.

  9. Monoclonal Antibody Aggregate Polish And Viral Clearance Using HIC 3/26/2024

    Explore highly productive POROS HIC polishing processes in both bind–elute and flowthrough modes that outcompeted legacy clinical processes designed for two highly challenging case studies (MAbs A and B).

  10. A Launchpad For Scalable Systems In AAV Gene Therapy Manufacturing 3/21/2024

    Identifying a trusted supplier that can address the myriad of challenges that accompany development for AAV-based drugs is critical to securing an asset’s ultimate commercial success.